HBM Holdings Limited (HKG:2142)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
13.13
-0.34 (-2.52%)
Apr 29, 2026, 4:08 PM HKT
57.43%
Market Cap 10.97B
Revenue (ttm) 1.23B
Net Income (ttm) 710.88M
Shares Out 835.74M
EPS (ttm) 0.86
PE Ratio 15.34
Forward PE 23.94
Dividend n/a
Ex-Dividend Date n/a
Volume 3,053,000
Average Volume 4,708,038
Open 13.47
Previous Close 13.47
Day's Range 12.93 - 13.47
52-Week Range 7.52 - 17.98
Beta 1.49
RSI 44.67
Earnings Date Aug 27, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 272
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2142
Full Company Profile

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD Financial Statements

News

There is no news available yet.